Clinical data
Trade names Ninlaro
AHFS/Drugs.com ninlaro
Routes of
Oral (capsules)
ATC code L01XX50 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 58%[1]
Protein binding 99%
Metabolism Hepatic (CYP: 3A4 (42%), 1A2 (26%), 2B6 (16%) and others)
Biological half-life 9.5 days
Excretion Urine (62%), feces (22%)
Synonyms MLN2238
CAS Number 1072833-77-2
PubChem (CID) 25183872
ChemSpider 25027391
UNII 71050168A2
KEGG D10130
ChEBI CHEBI:90942 YesY
Chemical and physical data
Formula C14H19BCl2N2O4
Molar mass 361.03 g·mol−1
3D model (Jmol) Interactive image

Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, developed by Takeda. It acts as a proteasome inhibitor and has orphan drug status in the US.

On November 20, 2015, the U.S. Food and Drug Administration approved ixazomib for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma after at least one prior therapy.[2]


Ixazomib is a peptide analogue that reversibly inhibits the protein proteasome subunit beta type-5 (PSMB5), which is part of the 20S proteasome complex.[3]


Ixazomib citrate—a prodrug for ixazomib
Ixazomib citrate—a prodrug for ixazomib

Ixazomib citrate is a prodrug which rapidly hydrolyzes under physiological conditions to its biologically active form, ixazomib.[1]


  1. 1 2 "Ninlaro (ixazomib) Capsules, for Oral Use. Full Prescribing Information" (PDF). NINLARO (ixazomib) For Healthcare Professionals. Takeda Pharmaceutical Company Limited. Retrieved 21 November 2015.
  2. "Press Announcements — FDA approves Ninlaro, new oral medication to treat multiple myeloma". U.S. Food and Drug Administration. Retrieved 24 April 2016.
  3. KEGG: Ixazomib
This article is issued from Wikipedia - version of the 8/17/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.